By a vote of 13 to one, the CDC’s Advisory Committee on Immunization Practices approved a reformulated COVID-19 vaccine for 2023-2024. The vaccine is set to arrive at pharmacies within days. Made by Moderna and Pfizer/BioNTech, this reworked formula targets current omicron variants like XBB, EG5 and BA286, which are now circulating in the U.S.
The panel recommended the shot for people ages six months and older, as the fall respiratory virus season nears and COVID-19 hospitalization rates tick slowly upward. Health experts recommend this new vaccine version. To read the full story.